This trial was conducted in North America. The aim of this clinical trial was to investigate if two formulations of NN1250 (insulin degludec) have the same level of drug exposure to the body.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
27
Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
Novo Nordisk Clinical Trial Call Center
Chula Vista, California, United States
Area under the Insulin Degludec concentration-time curve from 0 to 120 hours after single dose
Time frame: From 0 to 120 hours after dosing
Maximum observed Insulin Degludec concentration after single dose
Time frame: From 0 to 120 hours after dosing
Time to maximum observed Insulin Degludec concentration after single dose
Time frame: From 0 to 120 hours after dosing
Area under the Insulin Degludec concentration-time curve from 0 to 24 hours after single dose
Time frame: From 0-24 hours after dosing
Terminal half-life for Insulin Degludec
Time frame: From 0 to 120 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.